Clinical significance of UDP-glucuronosyltransferase 1A1*6 for toxicities of combination chemotherapy with irinotecan and cisplatin in gynecologic cancers

Oncology

Volumn 76, Issue 5, 2009, Pages 315-321

  Takano, Masashi ^c   Kato, Masafumi ^c   Yoshikawa, Tomoyuki ^c   Sasaki, Naoki ^c   Hirata, Junko ^c   Furuya, Kenichi ^c   Takahashi, Michiko ^a   Yokota, Harushige ^a   Kino, Nao ^a   Horie, Koji ^a   Goto, Tomoko ^b   Fujiwara, Keiichi ^b   Ishii, Kenji ^d   Kikuchi, Yoshihiro ^e   Kita, Tsunekazu ^c  

^a SAITAMA CANCER CENTER   (Japan)

^b SAITAMA MEDICAL UNIVERSITY   (Japan)

^c NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^d National Hospital Organization Nishisaitama Chuo National Hospital   (Japan)

^e Ohki Memorial Kikuchi Cancer Clinic for Women   (Japan)

Author keywords

Cisplatin; Gynecologic cancer; Irinotecan; UDP glucuronosyltransferase 1A1; UGT1A1; UGT1A1 6

Indexed keywords

CISPLATIN; GLUCURONOSYLTRANSFERASE 1A1; IRINOTECAN;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DNA POLYMORPHISM; DRUG WITHDRAWAL; ENZYME BLOOD LEVEL; FEMALE; GENETIC ASSOCIATION; GYNECOLOGIC CANCER; HUMAN; LEUKOPENIA; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVARY CARCINOMA; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT RESPONSE; UTERINE CERVIX CARCINOMA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CISPLATIN; FEMALE; GENOTYPE; GLUCURONOSYLTRANSFERASE; HUMANS; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; POLYMORPHISM, GENETIC; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 62449216350     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000209335     Document Type: Article

References (28)

1. Sugiyama T, Yakushiji M, Nishida T, et al: Irinotecan (CPT-11) combined with cisplatin in patients with refractory or recurrent ovarian cancer. Cancer Lett 1998; 128: 211-218.
2. Sugiyama T, Yakushiji M, Noda K, et al: Phase II study of irinotecan and cisplatin as first-line chemotherapy in advanced or recurrent cervical cancer. Oncology 2000; 58: 31-37.
3. Adachi S, Ogasawara T, Yamasaki N, et al: A pilot study of CPT-11 and cisplatin for ovarian clear cell adenocarcinoma. Jpn J Clin Oncol 1999; 29: 434-437.
4. Kita T, Kikuchi Y, Kudoh K, et al: Exploratory study of effective chemotherapy to clear cell carcinoma of the ovary. Oncol Rep 2000; 7: 327-331.
5. Takano M, Kikuchi Y, Yaegashi N, et al: Adjuvant chemotherapy with irinotecan hydrochloride and cisplatin for clear cell carcinoma of the ovary. Oncol Rep 2006; 16: 1301-1306.
6. de Forni M, Bugat R, Chabot GG, et al: Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patients. Cancer Res 1994; 54: 4347-4354.
7. Iyer L, King CD, Whitington PF, et al: Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest 1998; 101: 847-854.
8. Ciotti M, Basu N, Brangi M, Owens IS: Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38) by the human UDP-glucuronosyltransferases encoded at the UGT1 locus. Biochem Biophys Res Commun 1999; 260: 199-202.
9. Bosma PJ, Chowdhury JR, Bakker C, et al: The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N Engl J Med 1995; 333: 1171-1175.
10. Ando Y, Saka H, Ando M, et al: Polymorphisms of UDP- glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 2000; 60: 6921-6926.
11. Iyer L, Das S, Janisch L, et al: UGT1A1 * 28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J 2002; 2: 43-47.
12. Innocenti F, Undevia SD, Iyer L, et al: Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 2004; 22: 1382-1388.
13. Marcuello E, Altés A, Menoyo A, et al: UGT- 1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer. Br J Cancer 2004; 91: 678-682.
14. Rouits E, Boisdron-Celle M, Dumont A, et al: Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients. Clin Cancer Res 2004; 10: 5151-5159.
15. Liu JY, Qu K, Sferruzza AD, Bender RA: Distribution of the UGT1A1 * 28 polymorphism in Caucasian and Asian populations in the US: a genomic analysis of 138 healthy individuals. Anticancer Drugs 2007; 18: 693-696.
16. Mackenzie PI, Bock KW, Burchell B, et al: Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily. Pharmacogenet Genomics 2005; 15: 677-685.
17. Gagné J-F, Montminy V, Belanger P, et al: Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38). Mol Pharmacol 2002; 62: 608-617.
18. Jinno H, Tanaka-Kagawa T, Hanioka N, et al: Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38), an active metabolite of irinotecan (CPT-11), by human UGT1A1 variants, G71R, P229Q, and Y486D. Drug Metab Dispos 2003; 31: 108-113.
19. Han JY, Lim HS, Shin ES, et al: Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. J Clin Oncol 2006; 24: 2237-2244.
20. Sai K, Saito Y, Sakamoto H, et al: Importance of UDP- glucuronosyltransferase 1A1 * 6 for irinotecan toxicities in Japanese cancer patients. Cancer Lett 2008; 261: 165-171.
21. Hoskins JM, Goldberg RM, Qu P, et al: UGT- 1A1 * 28 genotype and irinotecan-induced neutropenia: dose matters. J Natl Cancer Inst 2007; 99: 1290-1295.
22. Hasegawa Y, Sarashina T, Ando M, et al: Rapid detection of UGT1A1 gene polymorphisms by newly developed Invader assay. Clin Chem 2004; 50: 1479-1480.
23. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors (RECIST) guidelines. J Natl Cancer Inst 2000; 92: 205-216.
24. UGT: UDP-Glucuronosyltransferase Alleles Nomenclature page. Adelaide, Flinders University School of Medicine, accessed May 20, 2008. http://som.flinders.edu.au/FUSA/ ClinPharm/UGT/
25. Haslam IS, Jones K, Coleman T, et al: Induction of P-glycoprotein expression and function in human intestinal epithelial cells (T84). Biochem Pharmacol 2008; 76: 850-861.
26. Bansal T, Awasthi A, Jaggi M, et al: Pre-clinical evidence for altered absorption and biliary excretion of irinotecan (CPT-11) in combination with quercetin: possible contribution of P-glycoprotein. Life Sci 2008; 83: 250-259.
27. Carlini LE, Meropol NJ, Bever J, et al: UGT- 1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. Clin Cancer Res 2005; 11: 1226-1236.
28. Fujita K, Ando Y, Nagashima F, et al: Genetic linkage of UGT1A7 and UGT1A9 polymorphisms to UGT1A1 * 6 is associated with reduced activity for SN-38 in Japanese patients with cancer. Cancer Chemother Pharmacol 2007; 60: 515-522.